請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/44420完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 江伯倫(Bor-Luen Chiang) | |
| dc.contributor.author | Yu-Cheng Wang | en |
| dc.contributor.author | 王友正 | zh_TW |
| dc.date.accessioned | 2021-06-15T02:56:34Z | - |
| dc.date.available | 2009-09-15 | |
| dc.date.copyright | 2009-09-15 | |
| dc.date.issued | 2009 | |
| dc.date.submitted | 2009-08-03 | |
| dc.identifier.citation | Adkinson, N.F.,Jr., Eggleston, P.A., Eney, D., Goldstein, E.O., Schuberth, K.C. and Bacon, J.R. (1997). A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med. 336: 324-331
Agrawal, s., Agrawal, A., Doughty, B., Gerwitz, A., Blenis, J., Van Dyke, T. and Puledran, B. (2003). Cutting edge: different Toll-like receptor agonists instruct dentritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol. 171: 4984-4989. Akbari, O., Dekruyff, R.H. and Umetsu, D.T. (2001). Pulmonary dendritic cells producting IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol. 2: 725-731. Akdis, M., Verhagen, J., Taylor, A,. Karamloo, F., Karagiannids, C., Crameri, R., Thunberg, S., Deniz, G., Valenta, R., Fiebig, H., Kegel, C., Disch, R., Schmidt-Weber, C.B., Blaser, K. And Akids C.A. (2004). Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specifc T regulatory 1 and T helper 2 cells. J Exp Med. 199: 1567-1575. Arshad, S.H., Kurukulaaratchy, R.J., Fenn, M. and Matthews, S. (2005). Early life risk factors for current wheeze asthma, and brochial hyperresponsiveness at 10 years of age. Chest. 127:502-508. Banchereau J. and Steinman R.M. (1998). Dendritic cells and the control of immunity. Nature. 392: 245-252. Barnes P. J. (1998). Anti-inflammatory action of glucocorticoids: molecular mechanisms. Clin Sci. 94: 557-572. Bellinghausen, I., Knop, J. and Saloga, J. (2001). The role of interleukin 10 in the regulation of allergic immune responses. Int Arch Allergy Immunol. 126: 97-101. Broide D.H. (2001). Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol. 108: S65-71. Brusselle, G.G., Kips, J. C., Joos, G., Bluethmann, H. and Pauwels, R. (1995). Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-40 deficient mice. Am J Respir Cell Mol Biol. 12: 254-259. Brusselle, G.G., Kips, J.C., Tavernier, J.H., van der Heyden, J.G., Cuvelier, C.A., Pauwels, R.A. and Bluethmann, H. (1994). Attenuation of allergic airway inflammation in IL-4 deficient mice. Clin Exp Allergy. 24: 73-80. Busse, W.W. and Lemanske, R.F., (2001). Asthma. N Engl J Med. 344: 350-362. Campbell, D., DeKruyff, R.H. and Umetsu, D.T. (2000). Allergen immunotherapy: novel approaches in the managenment of allergic diseases and asthma. Clin Immunol. 97: 193-202. Caux C., Massacrier C., Vanbervliet, B., Dubois, B., van Kooten, C., Durand, I. and Banchereau, J. (1998). Activation of human dendritic cells through CD40 crosslinking. J Exp Med. 180: 1263-1272. Cella, M., Sallusto, F. and Lanzavecchia, A. (1997a). Origin, maturation and antigen presenting function of dendritid cells. Curr Opin Immunol. 9: 10-16. Cella, M., Engering, A., Pinet, V. Pieters, J. And Lanzavecchia, A, (1997b). Inflammatory stimuli induce accumulation of MHC class II complexes on dentritic cells. Nature. 388: 782-787. Cella, M., Salio, M., Sakakibara, Y., Langen, H., Julkunen, I. and Lanzavecchia, A. (1999). Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med. 189: 821-829. Chiang, D.J., Ye, Y.L., Chen, W.L., Lee, Y.L., Hsu, N.Y. and Chiang, B.L. (2003). Ribavirin or CpG DNA sequence-modulated dendritic cells decrease the IgE level and airway inflammation. Am J Respir Crit Care Med. 168(5):575-580. Chuang, L.F., Chuang, T.K., Killam Jr., K.F., Chuang, A.J., Kung, H.F., Yu, L. and Chuang, R.Y. (1994). Delta opioid receptor gene expression in lymphocytes. Biochem. Biophys. Res Commun. 202:1291–1299. Chuang, L.F., Chuang, T.K., Killam Jr., K.F., Qiu, Q., Wang, X.R., Lin, J.J., Kung, H.F., Sheng, W., Chao, C., Yu, L. and Chuang, R.Y. (1995). Expression of kappa opioid receptors in human and monkey lymphocytes. Biochem. Biophys. Res Commun. 209: 1003–1010. Chung, K.F. and Barnes, P.J. (1999). Cytokines in asthma. Thorax 54: 825-857. Chuang, T.K., Killam, K.F. Jr., Chuang, L.F., Kung, H.F., Sheng, W.S., Chao, C.C., Yu, L. and Chuang, R.Y. (1995). Mu opioid receptor gene expression in immune cells. Biochem Biophys Res Commun. 216(3): 922-930. Cieslewicz, G., Tomkinson, A., Adler, A., Duez, C., Schwarze, J., Takeda, K., Larson, K.A., Lee, J.J., Irvin, C.G. and Gelfand, E.W. (1999). The late, but not early, asthmatic responses is dependent on IL-5 and correlates with eosinophil infiltration. J Clin Invest. 104: 301-308. Coffman, R.L., Ohara, J., Bond, M.W., Carty, J., Zlotnik, A. and Paul, W.E. (1986). B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells. J Immunol. 136: 4538-4541. Corrigan, C.J., Haczku, A., Gemou-Engesaeth, V., Doi, S., Kikuchi, Y. and Takatsu, K. (1993). CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5. Effect of glucocorticoid therapy. Am Rev Respir Dis. 147: 540-547. Corry, D.B. (1999). IL-13 in allergy: home at last. Curr Opin Immunol. 11: 610-614. Corry, D.B. and Kheradmand, F. (1999). Induction and regulation of the IgE response. Nature. 402: B18-23. Crabtree, B.L. (1984). Review of naltrexone, a long-acting opiate antagonist. Clin Pharmacol. 3: 273-280. de Jong, E.C., Smits, H.H. and Kapsenberg, M.L. (2005) Dendritic cell-mediated T cell polarization. Springer Semin Immnopathol. 26: 289-307. DeKruyff, R.H., Fang, Y., Wolf, S.F. and Umetsu, D.T. (1995). IL-12 inhibits IL-4 synthesis in keyhole limpet hemocyanin-primed CD4+ T cells through an effect on antigen-presenting cells. J Immunol. 154: 2578-2578. Dent, L.A. Strath, M., Mellor, A.L. and Sanderson, C.J. (1990), Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med. 172: 1425-1431. Dompeling E., Jöbsis, R. and van Schayck, O. (2000). Siblings, day-care attendance, and the rick of asthma and wheezing. N Engl J Med. 343(26): 1967. Dow, S.W., Schwarze, J., Heath, T.D., Potter, T.A. and Gelfand, E.W. (1999). Systemic and local interferon gamma gene delivery to the lungs for treatment of allergen-induced airway hyperresponsiveness in mice. Hum Gene Ther. 10: 1905-1914. Durtham, S.R., Ying, S., Varney, V.A., Jacobson, M.R. Mackay, I.S., Kay, A.B. and Hamid, Q.A. (1996). Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinopils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol. 97(6): 1356-1365. Finley, M.J., Happel, C.M., Kaminsky, D.E. and Rogers, T.J. (2008). Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression. Cell Immunol. 252(1-2): 146-54. Foster, P.S., Hogan, S.P., Ramsay, A.J., Matthaei, K.I. and Young, I.G. (1996). Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med. 172: 1425-1431. Gallowway, G. and Hayner, G. (1993). Haight-Ashbury free clinics drug detoxification protocols. J Psychoactive Drugs. 25: 251-252. Gaveriaux, C., Peluso, J., Simonin, F., Laforet, J. and KieVer, B. (1995). Identiffcation of kappa- and delta-opioid receptor transcripts in immune cells. FEBS Lett. 369: 272–276. Gavett, S.H. O`Hearn, D.J. Karp, C.L., Patel, E.A., Schofield, B.H., Finkelman, F.D. and Wills-Karp, M. (1997). Interleukin-4 receptor blockade prevents airway resposes induced by antigen challenge in mice. Am J Physiol. 272: L253-L261. Geha, R.S., Jabara, H.H. and Brodeur, S,R, (2003). The regulation of immunoglobulin E class-switch recombination. Nat Rev Immunol. 3: 7211-732. Gemou-Engesaeth, V., Fagerhol, M.K., Toda, M,, Hamid, Q., Halvorsen, S., Groegaard, J.B. and Corrigan, C.J., (2002). Expression of activation markers and cytokine mRNA by peripheral blood CD4 and CD8 T cells in atopic and nonatopic childhood asthma: effect of inhaled glucocorticoid therapy. Pediatrics. 109: E24. Griffiths-Johnson, D.A., Collins, P.D., Rossi, A.G., Jose, P.J. and William, T.J. (1993). The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and cause their accumulation into the lung in vivo. Biochem Biophys Res Commum, 197: 1167-1172. Grunewald, S.M., Werthmann, A., Schnarr, B., Klein, C.E., Brocker, E.B. and Mohrs, M. (1998). An antagonistic IL-4 mutant prevent type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completly abrogates humoral immune response to allergen and development of allergic symptom in vivo. J Immunol. 160: 4004-4009. Hamid, Q.A. and Minshall, E.M. (2000) Molecular pathology of allergic disease: I: lower airway disease. J Allergy Clin Immunol. 105: 20-36. Hartmann, G., Weiner, G.J. and Krieg, A.M. (1999) CpG DNA: a potent signal for growth , activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA. 96: 9305-9310. Herz, U., Braun, A., Rucket, R. and Renz, H. (1998). Various immunological phenotypes are associated with increased airway responsiveness. Clin Exp Allergy. 28: 625-634. Hocking, W. and D, Golde. (1979). The pulmonary alveolar macrophage. N Engl J Med. 301:580–587, 639–644. Huang, J.L. (2005). Asthma severity and genetics in Taiwan. J Microbiol Immuno Infect. 38: 158-163. Humbert, M., Durham, S.R., Kimmitt, P., Powell, N., Assoufi, B., Pfister, R., Menz, G., Kay, A.B. and Corrigan, C.J. (1997). Elevated expression of messenger ribonucleic acid encding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immumol. 99: 657-665. Jakob T., Walker, P.S. Krieg, A.M., Udey, M.C. and Vogel, J.C. (1998). Activation of cutaneous dendritic cells by CpG-containing oligodeoxynuleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol. 161: 3042-3049. Jean, M.B., Maxim, K., Amy, L.P., Sarah, S., Baoyong, S. and Christopher, M.T. (2006), opioid receptors and signaling on cells from the immune system. J Neuroimmune Pharmacol. 1: 260–269. Kline J.N., Waldschmidt, T.J., Businga, T.R., Lemish, J.E. Weinstock, J.V., Thone, P.S. and Krieg, A.M. (1998). Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol. 160(6):2555-2559. Kobayashi, T., Miura, T., Haba, T., Sato, M., Serizawa, I., Nagai, H., and Ishizaka, K. (2000). An essential role of mast cells in the development of airway hyperresponsiveness in a murine asthma model. J Immunol. 164: 3855-3861. Kosten, T.R. and George, T.P. (2002). The neurobiology of opioid dependence: Implications for treatment. Sci Pract Perspect. 1(1):13-20. Kosten, T.R. and Kleber, H.D., (1984). Strategies to improve compliance with narcotic antagonists. Am J Drug Alcohol Abuse. 10(2): 249-66. Kraus J., Borner C., Giannini E., Hickfang K., Braun H., Mayer P., Hoehe M.R., Ambrosch A., Konig W. and Hollt V. (2001). Regulation of muopioid receptor gene transcription by interleukin-4 and influence of an allelic variation within a STAT6 transcription factor binding site. J Biol Chem. 276: 43901–43908. Kurup, V.P., Murali, P.S., Guo, J., Choi, H., Banerjee, B. Fink, J.N. and Coffman, R.L. (1997). Anti-interleukin (IL)-4 and IL-5 antibodies downregulate IgE and eosinophilia in mice exposed to Aspergillus antigens. Allergy. 52: 1215-1221. Lambrecht, B.N., De Veerman, M., Coyle, A.J., Gutierrez-Ramos, J.C. Thielemans, K. and Pauwels, R.A. (2000). Myeliod dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J Clin Invest. 106:551-559. Lee, Y.L., Fu, C.L., Ye, Y.L. and Chiang, B.L. (1999a). Administration of interleukin-12 prevents mite Der p I allergen-IgE antibody production and airway eosinophil infiltration in an animal model of airway inflammation. Scand. J. Immunol. 49: 229–236. Lee, Y.L., Ye, Y.L., Yu, C.I., Wu, Y.L., Lai, Y.L., Ku, P.H., Hong, R.L. and Chiang, B.L. (2001). Construction of single-chain interleukin-12 DNA plasmid to treat airway hyperresponsiveness in an animal model of asthma. Hum Gene Ther. 12(17):2065-2079 Leong, K.P. and Huston, D.P. (2001) Understanding the pathgenesis of allergic asthma using mouse model. Ann Allergy Asthma Immuno. 87: 96-109. Li, L., Xia, Y., Nguyen, A., Lai, Y.H., Feng, L., Mosmann, T.R. and Lo, D. (1999) Effects of Th2 cytokines on chemokine expression ni the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J Immunol. 162: 2477-2487. Li, X.M., Chopra, R.K., Chou, T.Y., Schofield, B.H., Wills-Karp, M. and Huang, S.K. (1990). Mucosal IFN-gamma gene transfer inhibits pulmonary allergic responses in mice. J Immunol. 157:3216-3219. Lin, S.L., Lee, Y.M., Chang, H.Y., Cheng, Y.W. and Yen, M.H. (2005). Effects of naltrexone on lipopolysaccharide-induced sepsis in rats. J Biomed Sci. 12(2): 431-40. Linner, K.M., Quist, H.E. and Sharp, B.M. (1995). Met-enkephalin-containing peptides encoded by proenkephalin A mRNA expressed in activated murine thymocytes inhibit thymocyte proliferation. J. Immunol. 154: 5049–5060. Liu, M.C. Hubbard, W.C. Proud, D. Stealey, B.A., Galli, S.J., Kagey-Sobotka, A., Blacker, E.R. and Lichtenstein, L.M. (1991). Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. Am Rev Respir. 144(1):51-58. Liu, Y.J., Kanzler, H., Soumelis, V. And Gilliet, M. (2001). Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol. 2:585-589. Lohmann-Matthes, M., Steinmuller, C. and Franke-Ullmann, G. (1994). Pulmonary macrophages. Eur Respir J. 7:1678–1689. Lukacs, N.W., Strieter, R.M., Chensue, S.W. and Kunkel, S.L. (1994). Interleukin-4-dependent pulmonary eosinophil infiltration in a murine model of asthma. Am J Respir Cell Mol Biol. 10: 526-532. Makarenkova V.P., Esche C., Kost N.V., Shurin G.V., Rabin B.S., Zozulya A.A. and Shurin M.R. (2001) Identification of delta- and mu-type opioid receptors on human and murine dendritic cells. J Neuroimmuno.l 117: 68–77. Mathur, M., Herrmann, K., Li, X., Qin, Y., Weinstock, J., Elliott, D., Monahan, J. and padrid, p. (1999). TRFK-5 reverses established airway eosinophilia but not established hyperresponsivevess in a murine model of Th1 cells from naїve CD4(+) T cells. J Immunol. 154: 5071-5079. Milgrom, H., Fick, R.B. Jr., Su, J.Q., Reimann, J.D., Bush, R.K., Watrous, M.L. and Metzger, W.J. (1999). Treatment of allergic asthma with monoclonal anti-IgE antibody rhuMAb-E25 Study Gourp. N Engl J Med. 341(26):1966-1973. Moore, K.W., de Waal Malefyt, R., Coffman, R.L. and O`Garra, A. (2001). Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 19: 683-765. Mould, A.W., Mattaei, K.I., Young, I.G. and Foster, P.S. (1997). Relationship between interleukin-5 and eotaxin in regulating blood and tissue eosinophilia in mice. J Clin Invest. 99: 1064-1071. Mutius, E. (2000). The environmental predictors of allergic disease. J Allergy Clin Immunol. 105: 9-19. Nadel, J.A. and Busse, W.W. (1998). Asthma. Am J Respir Crit Care Med. 157: S130-138. Nakjima, H., Nakao, A., Watanbe, Y., Yoshida, S. and Iwamoto, I. (1994). IFN-alpha inhibits antigen-induced eosinophil and CD4+ T cell recruitment into tissue. J Immunol. 153: 1264-1270. National Heart, Lung, and Blood Institute and National Asthma Education Program. (1999). Guidelines for the diagnosis and management of asthma. Expert Panel Report. J Allergy Clin Immunol. 88: 425-534. Nationale Heart, Lung, and Blood Institute and National Institutes of Health. (1992). International consensus report on diagnosis and treatment of asthma. Bethesda, Maryland 20892. Eur Rspir J. 5(5): 601-641. Noon, L., Prophylactic inoculation against hay fever. Lancet 1911; 1:1572 Peng, X., Mosser, D.M., Adler, M.W., Rogers, T.J., Meissler, J.J., Jr. and Eisenstein,T.K. (2000). Morphine enhances interleukin-12 and the production of other pro-inflammatory cytokines in mouse peritoneal macrophages.J Leukoc Biol. 68(5): 723-8. Peters-Golden, M. (2004). The alveolar macrophage: the forgotten cell in asthma. Am J Respir Cell Mol Biol. 31(1): 3-7. Piccinni, M.P., Maggi, E. and Romagnani, S. (2000). Environmental factor favoring the allergen-specific Th2 response in allergic subjects. Ann NY Acad Sci. 917: 844-852. Poole, J.A., Matangkasombut, P., and Rosenwasser, L.J. (2005). Targeting the IgE molecule in allergy and asthmatic diseases: review of the IgE molecule and clinical efficacy. J Allergy Clin Immunol. 115: S376-385. Ramirez N.C. and Ledford, D.K. (2002) Immunotherapy for allergic asthma. Med Clin North Am. 86(5):1091-1112. Rankin, S.M., Conroy, D.M. and Williams, T.J. (2000). Eotaxin and eosinophil recruitment: implication for human disease. Mol Med Today. 6: 20-27. Rautava, S., Ruuskanen, O., Ouwehand, A., Salminen, S. and Isolauri, E. (2004). The hygiene hypothesis of atopic disease--an extended version. J Pediatr Gastroenterol Nutr. 38: 378-388. Renauld, J.C. (2001). New insights into the role of cytokines in asthma. J Clin Pathol. 54: 577-589. Rocklin, R.E., Sheffer A.L., Greineder, D.K. and Melmon, K.L. (1980). Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med. 302(22): 1213-1219. Romagnani, S. (1994). Lymphokine production by human T cells in disease states. Annu Rev Immunol. 12: 227-257. Rothenberg, M.E., MacLean, J.A., Pearlman, E., Luster, A.D. and Leder, P. (1997). Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J Exp Med. 185: 785-790. Sacerdote, P., Manfredi, B., Gaspani, L. and Panerai, A.E. (2000). The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in BALB/cJ mice. Blood. 95(6): 2031-2036. Schwarze, J., Hamelmann, E., Cieslewicz, G., Tomkinson, A., Joetham, A, Bradley, K. and Gelfand, E.W. (1998). Local treatment with IL-12 is an effective inhibitor of airway hyperresponsiveness and lung eosinophilia after airway challenge in sensitized mice. J Allergy Clin Immunol. 102: 86-93. Sedqi, M., Roy, S., Ramakrishnan, S., Elde, R. and Loh, H.H. (1995). Complementary DNA cloning of a mu-opioid receptor from rat peritoneal macrophages. Biochem. Biophys. Res. Commun. 209: 563–574. Segal, D.M., Taurog, J.D. and Metzger, H. (1977). Dimeric immunoglobulin E serves as unit signal for mast cell degranulation. Proc Natl Acad Sci USA. 74(7):2993-2997. Shahabi, N.A., Heagy, W. and Sharp, B.M. (1996). Beta-endorphin enhances Concanavalin-A-stimulated calcium mobilization by murine splenic T cells. Endocrinology. 137: 3386–3393. Shahabi, N.A. and Sharp, B.M.,(1995). Antiproliferative effects of delta opioids on highly puriffed CD4+ and CD8+ murine T cells. J Pharmacol Exp Ther. 273: 1105–1113. Shardonofsky, F.R., Venzor, Jr., Barrios, R., Leong, K.P. and Huston, D.P. (1999). Therapeutic efficacy of an anti-IL-5 monoclonal antibody delivered into the respiratory tract in a murine model of asthma. J Allergy Clin Immunol. 104: 215-221. Sharp, B.M. (2006). Multiple opioid receptors on immune cells modulate intracellular signaling. Brain Behav Immun. 20(1): 9-14. Sherrill, D., Stein, R., Kurzius-Spencer, M. and Martinez, F. (1999). On early sensitization to allergens and development of respiratory symptom. Clin Exp Allergy. 29: 905-911. Shimizu, T., Mochizuki, H. and Morikawa, A. (1997). Effect of influenza A virus infection on acid-induced cough response in children with asthma. Eur Respir J. 10: 71-74. Sibinga, N.E.S. and Goldstein, A. (1988). Opioid peptides and opioid receptors in cells of the immune system. Annu Rev Immunol. 6:219–249. Sigurs, N., Gustafsson, P.M., Bjarnason, R., Lundberg, F., Schmidt, S., Sigurbergsson, F. and Kjellman, B. (2005). Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Cril Care Med. 171: 137-141. Sokol, C.L., Barton, G.M., Farr, A.G. and Medzhitov, R. (2008). A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat. Immunol. 9: 310–318. Stone, N.N. (1994). Nalmefene in the treatment of interstitial cystitis. Urol Clin North Am. 21: 101-106. Strachan, D.P. (1989). Hay fever, hygiene, and houseohold size. Brit Med J. 299: 1259-1260. Sung, S., Rose, C.E. and Fu, S.M. (2001). Intratracheal priming with ovalbumin-and ovalbumin 323-339 peptide-pulsed dendritic cells induces airway hyperresponsiveness, lung eosinophilia, goblet cell hyperplasia, and inflammation. J Immunol. 166: 1261-1271. Sur, S., Wild, J.S., Choudhury, B.K., Sur, N., Alam, R. and Klinman, D.M. (1999). Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol. 162: 6284-6293. Sutton, B.J. and Gould, H.J. (1993). The human IgE network. Nature. 366(6454): 421-428. Swain, S.L. Weinberg, A.D., English, M, and Huston, G. (1990). IL-4 directs the development of Th2-like helper effectors. J Immunol. 145: 3796-3806. Tomkinson, A., Cieslewicz, G., Duez, C., Larson, K.A., Lee, J.J. and Gelfand, E.W. (2001). Temporal association between airway hyperresponsiveness and airway eosinophilia in ovalbumin-sensitized mice. Am J Respir Crit Care Med. 163: 721-730. Turner, H. and Kinet, J.P. (1999). Signalling through the high-affinity IgE receptor Fc epsilonRI. Nature. 402:B24-B30. Valenta, R. (2002) The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol. 2: 446-453. Van Oosterhout, A.J., Ladenius, A.R., Savelkoul, H.F., Van Ark, I., Delsman, K.C. and Nijkamp, F.P. (1993). Effect of anti-IL-5 and IL-5 on airway hyperreactivity and eosinophis in guinea pigs. Am Rev Respir Dis. 147: 548-552. von Hertzen, L.C. and Haahtela, T. (2000). Could the risk of asthma and atopy be reduced by a vaccine that induces a strong T-helper type I response? Am J Respir Cell Mol Biol. 22: 139-142. Walker, J.S. (2003). Anti-inflammatory effects of opioids. Adv Exp Med Biol. 521: 148-60. Wang, D.S., Sternbach, G. and Varon, J. (1998). Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine. J Emerg Med. 16(3): 471-5. Weiss, S.T. Eat dirt--the hygiene hypothesis and allergic diseases. (2002). N Engl J Med. 347(12): 930-931. Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T.Y. and Karp, C.L. (1998). IL-13: central mediator of allergic asthma. Science. 282: 2258-2261. Woolcock, A.J. and Peat, J.K. (1997). Evidence for the increase in asthma worldwide. Ciba Found Symp. 206: 122-134. Wybran, J., Appelboom, T., Famaey, J.P.and Govaerts, A. (1979). Suggestive evidence for receptors for morphine and methionine-enkephalin on normal human blood T lymphocytes. J Immunol. 123: 1068–1070. Ye, Y.L., Huang, W.C. Lee, Y.L. and Chiang, B.L. (2002). Interleukin-12 inhibits eotaxin secretion of cultured primary ling cells and alleviates airway inflammation in vivo. Cytokine. 19: 76-84. Zhou, C.Y., Crocker, I.C., Koening, G., Romero, F.A. and Townley, R.G. (1997). Anti-interleukin-4 inhibits immunoglobulin E production in a murine model of atopic asthma. J Asthma. 34: 195-201. Zuany-Amorim, C., Haile, S., Leduc, D., Dumarey, C., Huerre, M., Vargaftig, B.B. and Pretolani, M., (1995). Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice. J Clin Invest. 95: 2644-2651. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/44420 | - |
| dc.description.abstract | 氣喘是現在工業化社會常見的慢性呼吸道發炎性疾病，在許多開發中國家或已開發國家中非常普遍，主要造成氣喘的原因是遺傳因子、環境影響以及生活型態。氣喘的發生主要是T輔助型細胞的不正常偏向Th2細胞型免疫反應所導致，其症狀為間歇性與可逆性之呼吸道阻礙造成之週期性氣喘、胸腔緊繃與呼吸急促、支氣管過度敏感以及慢性的呼吸道發炎等。
已有許多研究指出類鴉片接受器位於免疫細胞上，參與調節免疫反應。納美芬與納美芬酮是一種類鴉片受體的對抗劑，可以透過阻斷類鴉片受體來達到抗發炎效果。所以本實驗主要目的是探討納美芬與納美芬酮在氣喘動物模式中抑制小鼠呼吸道發炎反應的效果。 在體外實驗中發現，經LPS刺激後的樹突細胞與巨噬細胞以納美芬與納美芬酮處理，可以使得IL-6、IL-12、IL-10與TNF-α的表現量明顯降低，顯示出納美芬與納美芬酮可以有效的抑制發炎相關的細胞激素表現。所以進一步，想利用卵清蛋白誘導小鼠的氣喘動物模式去研究納美芬與納美芬酮在動物實驗中之抗發炎效果，將實驗小鼠分為七組，每組約5–6隻，各組分別以不同方式處理。小鼠犧牲後，分析其呼吸道阻力、肺功能、引起發炎相關的細胞激素及趨化因子與卵清蛋白專一性抗體可以發現，在動物實驗中納美芬與納美芬酮可以有效抑制呼吸道阻力產生，且可以減少在肺沖洗液中與發炎相關的細胞激素與趨化因子eotaxin、IL-6與TNF-α之分泌，以及抑制嗜酸性白血球之聚集現象，但是卻不會影響血清中抗原專一性的抗體分泌與肺沖洗液中的IL-5分泌，而在脾臟細胞之IL-5、IL-10與IL-12之分泌與細胞增生反應的狀況亦不會受到影響。因此可推論納美芬與納美芬酮應可以透過阻斷類鴉片接受器方式抑制發炎反應，改善氣喘中呼吸道的發炎反應，但是卻不會影響免疫反應的走向。但是由於詳細的作用機制仍然不明確，所以未來仍有待進一步的研究去確認。 | zh_TW |
| dc.description.abstract | Asthma is one of the most common airway inflammatory disease in the industrialized society and is the prevalence is very high in developed and developing countries. It might be caused by many factors including genetic factors, environmental factors and life style. The immune mechanism of asthma is that T helper cells are abnormally differentiated to Th2 immune response. The symptoms of asthma are intermittent and reversible airway obstruction leading to recurrent episodes of wheezing, breathlessness, chest tightness, and cough; bronchial hyperresponsiveness (BHR), which is defined as an increased sensitivity to bronchoconstrictors such as histamine or cholinergic agonists; and airway inflammation. Many researches have indicated that opioid receptors are found on immune cells, and participate in regulation of immune response. Naltrexone and nalmefene are antagonists of opioid receptors, and they can suppress inflammation with blocking the opioid receptors. For this reason, the aim of this study is to find out if naltrexone and nalmefene could suppress airway inflammation in OVA-induced murine model of asthma. The secretion of IL-6, IL-12, IL-10 and TNF-α of dentritic cells and macrophages stimulated with LPS were decreased by treatment with naltrexone and nalmefene. These results showed that naltrexone and nalmefene can reduce the secretion of cytokines related with inflammation. Further, in the OVA-induced murine model of asthma, analyzing the AHR, lung fuction, cytokines and chemokines which is related to inflammation suggesting that naltrexone and nalmefene can suppress the AHR and eosinophils assembling, and reduce the production of cytokines and chemokines connected with inflammation such as eotaxin, IL-6 and TNF-α in BALF. However, naltrexone and nalmefene can not affect the levels of antigen-specific antibodies in serum and the production of IL-5 in BALF, and have no effect in the levels of IL-5, IL-10 and IL-12 produced by splenocytes. Therefore, the results of study suggest that naltrexone and nalmefene can suppress the inflammation by blocking the opioid receptor, and reduce the airway inflammation in asthma, but have no effect to change the immune response. Finally, the mechanisms are not clear, so it needs futher investigation further in the future. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T02:56:34Z (GMT). No. of bitstreams: 1 ntu-98-R95450014-1.pdf: 2165348 bytes, checksum: 462e22d986ae9225cf2fdbdba6405b8f (MD5) Previous issue date: 2009 | en |
| dc.description.tableofcontents | 口試委員審定書………………………………………………………………………1
致謝……………………………………………………………………………2 中文摘要………………………………………………………………………4 英文摘要……………………………………………………………………… 5 縮寫對照表…………………………………………………………………………7 目錄…………………………………………………………………………… 8 第一章 研究背景…………………………………………………………… 11 1-1. 氣喘疾病之介紹……………………………………………………… 12 1-2. 衛生假說………………………………………………………13 1-3. 氣喘疾病的致病過程………………………………………………… 13 1-4. 氣喘疾病的產生機制……………………………………………… 14 1-5. 氣喘疾病的調控………………………………………………………… 15 1-6. 參與氣喘疾病的細胞與IgE抗體及其扮演之角色…………………… 18 1-7. 氣喘動物模式的建立………………………………………………… 20 1-8. 治療氣喘的方式…………………………………………………… 20 1-9. 類鴉片接受器的介紹………………………………………………… 22 1-10. Naltrexone與Nalmefene之介紹………………………………… 23 第二章 研究動機與目的…………………………………………………… 25 第三章 探討納美芬與納美芬酮在樹突細胞及巨噬細胞培養中的抗發炎效果………………………………………………………………… 27 3-1. 研究方法與材料………………………………………………… 28 3-1-1. 小鼠來源……………………………………………………… 28 3-1-2. 培養樹突細胞………………………………………………… 28 3-1-3. 培養巨噬細胞………………………………………………… 29 3-1-4. 螢光流式細胞儀…………………………………………………29 3-1-5. 測量細胞激素…………………………………………………30 3-1-6. 統計方法………………………………………………………… 31 3-2. 實驗結果……………………………………………………………… 31 3-2-1. 樹突細胞的培養狀況……………………………………………31 3-2-2. 巨噬細胞之培養狀況…………………………………………32 3-2-3. Naltrexone與Nalmefene對以LPS刺激的樹突細胞之細胞激素分泌量之影響…………………………………………………………… 32 3-2-4. Naltrexone與Nalmefene對以LPS刺激的巨噬細胞之細胞激素分泌量之影響…………………………………………………………… 33 第四章 探討納美芬與納美芬酮在氣喘之小鼠動物模式中的抗發炎效果………………………………………………………………………34 4-1. 研究方法與材料……………………………………………………… 35 4-1-1. 小鼠來源………………………………………………………… 35 4-1-2. 建立對OVA過敏之氣喘動物模式及治療……………………… 35 4-1-3. 測量對OVA有專一性之血清抗體……………………………… 36 4-1-4. 呼吸道阻力測試……………………………………………………37 4-1-5. 肺沖洗液之收集………………………………………………… 38 4-1-6. 肺沖洗液中血球分類計算……………………………………… 38 4-1-7. 肺沖洗液中細胞激素及發炎介質分泌量之測量…………………38 4-1-8. 脾臟細胞之收集取得………………………………………………40 4-1-9. OVA專一性之脾臟增生反應………………………………………40 4-1-10. OVA專一性抗原刺激脾臟細胞之細胞激素測量…………………41 4-1-11. 統計方法……………………………………………………………42 4-2. 實驗結果…………………………………………………………………42 4-2-1. 氣喘動物模式的OVA專一性抗體IgE、IgG1及IgG2a的表現狀況……………………………………………………………………42 4-2-2. Naltrexone與Nalmefene對於呼吸道阻力的治療效果………43 4-2-3. 以Naltrexone與Nalmefene治療過後小鼠肺部之細胞激素與發炎介質的分泌量變化…………………………………………………43 4-2-4. 以Naltrexone與Nalmefene治療過後對小鼠肺部之嗜酸性白血球聚集的影響……………………………………………………44 4-2-5. 以Naltrexone與Nalmefene治療小鼠過後對OVA專一性脾臟細胞增生反應之影響………………………………………………44 4-2-6. 以Naltrexone與Nalmefene治療小鼠過後對OVA專一性刺激之脾臟細胞的細胞激素分泌量影響………………………………44 第五章 討論………………………………………………………………………46 圖…………………………………………………………………………………52 參考文獻……………………………………………………………………………72 | |
| dc.language.iso | zh-TW | |
| dc.subject | 納美芬酮 | zh_TW |
| dc.subject | 氣喘 | zh_TW |
| dc.subject | 類鴉片接受器 | zh_TW |
| dc.subject | 抗發炎反應 | zh_TW |
| dc.subject | 納美芬 | zh_TW |
| dc.subject | nalmefene | en |
| dc.subject | asthma | en |
| dc.subject | anti-inflammation | en |
| dc.subject | opioid receptor | en |
| dc.subject | naltrexone | en |
| dc.title | 研究纳美芬與纳美芬酮之抗發炎效果以減緩氣喘之呼吸道發炎反應 | zh_TW |
| dc.title | Application of Naltrexone and Nalmefene for alleviation of airway inflammation in OVA-induced murine model of asthma | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 97-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 吳文勉,李岳倫(Yueh-Lun Lee) | |
| dc.subject.keyword | 氣喘,類鴉片接受器,抗發炎反應,納美芬,納美芬酮, | zh_TW |
| dc.subject.keyword | asthma,anti-inflammation,opioid receptor,naltrexone,nalmefene, | en |
| dc.relation.page | 86 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2009-08-03 | |
| dc.contributor.author-college | 牙醫專業學院 | zh_TW |
| dc.contributor.author-dept | 口腔生物科學研究所 | zh_TW |
| 顯示於系所單位： | 口腔生物科學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-98-1.pdf 未授權公開取用 | 2.11 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。